PE20021097A1 - Inmunoconjugados de anticuerpos cd44 citotoxicos - Google Patents

Inmunoconjugados de anticuerpos cd44 citotoxicos

Info

Publication number
PE20021097A1
PE20021097A1 PE2002000420A PE2002000420A PE20021097A1 PE 20021097 A1 PE20021097 A1 PE 20021097A1 PE 2002000420 A PE2002000420 A PE 2002000420A PE 2002000420 A PE2002000420 A PE 2002000420A PE 20021097 A1 PE20021097 A1 PE 20021097A1
Authority
PE
Peru
Prior art keywords
compound
specific
antibody
vff
formula
Prior art date
Application number
PE2002000420A
Other languages
English (en)
Inventor
Gunther Adolf
Marlies Sproll
Erik Patzelt
Karl-Heinz Heider
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20021097A1 publication Critical patent/PE20021097A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA A(LB)n DONDE A ES UN ANTICUERPO ESPECIFICO PARA CD44, L ES UN RESTO ENLAZADOR, B ES UN COMPUESTO QUE ES TOXICO PARA LAS CELULAS COMO UN MAITANSINOIDE DE FORMULA I DONDE R1 ES H, SR4 DONDE R4 ES METILO, ETILO, ALQUILO; R2 EL Cl, H; R3 ES O, CH3; m ES 1-3 DE PREFERENCIA N2'-DESACETIL-N2'-(3-MERCAPTO-1-OXOPROPIL)MAITANSINA Y n ES 1-10. EL COMPUESTO DONDE DICHO RESTO ENLAZADOR TIENE UN ENLACE QUIMICO DISULFURO CAPAZ DE SER ROTO EN EL INTERIOR DE LA CELULA. LA MOLECULA DE ANTICUERPO ES ESPECIFICA PARA EL EXON v6 DE CD44 HUMANO O ESPECIFICA PARA UN EPITOPO DENTRO DE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO :3. LA MOLECULA DE ANTICUERPO ES MONOCLONAL VFF-18 (DSM ACC2174) O UN ANTICUERPO RECOMBINANTE QUE TIENE LAS REGIONES DETRMINANTES DE LA COMPLEMENTARIDAD (CDR) DE VFF-18.
PE2002000420A 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos PE20021097A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112227A EP1258255A1 (en) 2001-05-18 2001-05-18 Conjugates of an antibody to CD44 and a maytansinoid

Publications (1)

Publication Number Publication Date
PE20021097A1 true PE20021097A1 (es) 2003-02-13

Family

ID=8177473

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000420A PE20021097A1 (es) 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos

Country Status (24)

Country Link
EP (2) EP1258255A1 (es)
JP (1) JP2004529963A (es)
KR (1) KR20030097883A (es)
CN (1) CN1509187A (es)
AR (1) AR035977A1 (es)
BG (1) BG108366A (es)
BR (1) BR0209862A (es)
CA (1) CA2443438A1 (es)
CO (1) CO5550468A2 (es)
CZ (1) CZ20033477A3 (es)
EA (1) EA200301159A1 (es)
EE (1) EE200300568A (es)
HR (1) HRP20030932A2 (es)
HU (1) HUP0400046A3 (es)
IL (1) IL157965A0 (es)
MX (1) MXPA03010432A (es)
NO (1) NO20035108L (es)
NZ (1) NZ530167A (es)
PE (1) PE20021097A1 (es)
PL (1) PL365480A1 (es)
SK (1) SK15582003A3 (es)
WO (1) WO2002094325A2 (es)
YU (1) YU91503A (es)
ZA (1) ZA200307364B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
PT1651162E (pt) * 2003-05-20 2016-02-22 Immunogen Inc Agentes citotóxicos melhorados compreendendo novos maitansinóides
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
BRPI0412879A8 (pt) * 2003-07-21 2015-12-15 Immunogen Inc Conjugado citotóxico específico do antígeno ca6 e métodos de seu uso
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
ES2539126T3 (es) 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
WO2006099141A2 (en) 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
RS52470B (en) 2005-08-24 2013-02-28 Immunogen Inc. PROCEDURE FOR PREPARATION OF PURE CONJUGATED MEDICINES
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
CN102448500A (zh) 2009-06-03 2012-05-09 免疫基因公司 轭合方法
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
EA201991268A3 (ru) 2011-03-29 2020-01-31 Иммуноджен, Инк. Получение конъюгатов "майтансиноид-антитело" одностадийным способом
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
RU2018122734A (ru) 2012-10-04 2018-07-24 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент-цитотоксический агент
GB201220891D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220889D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
CN105530942B (zh) 2013-08-26 2019-10-11 瑞泽恩制药公司 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
WO2019161528A1 (en) * 2018-02-22 2019-08-29 Abmart Shanghai Co., Ltd. Therapeutic antibody and uses thereof
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
DK2803367T3 (en) * 1999-06-25 2018-04-16 Immunogen Inc Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
EP2266607A3 (en) * 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer

Also Published As

Publication number Publication date
HUP0400046A3 (en) 2006-02-28
NO20035108D0 (no) 2003-11-17
BR0209862A (pt) 2004-06-08
JP2004529963A (ja) 2004-09-30
CN1509187A (zh) 2004-06-30
NO20035108L (no) 2003-11-17
MXPA03010432A (es) 2004-04-02
KR20030097883A (ko) 2003-12-31
EP1258255A1 (en) 2002-11-20
CA2443438A1 (en) 2002-11-28
WO2002094325A2 (en) 2002-11-28
CZ20033477A3 (en) 2004-05-12
CO5550468A2 (es) 2005-08-31
IL157965A0 (en) 2004-03-28
EA200301159A1 (ru) 2004-06-24
NZ530167A (en) 2005-10-28
AR035977A1 (es) 2004-07-28
HRP20030932A2 (en) 2004-04-30
SK15582003A3 (sk) 2004-04-06
BG108366A (bg) 2004-09-30
EE200300568A (et) 2004-04-15
PL365480A1 (en) 2005-01-10
EP1395290A2 (en) 2004-03-10
ZA200307364B (en) 2004-04-20
HUP0400046A2 (hu) 2004-04-28
WO2002094325A3 (en) 2003-04-17
YU91503A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
PE20021097A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos
DE60205891D1 (de) Steroide als agonisten für fxr
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
CO5040071A1 (es) Derivados de aminas biciclicas, procesos para su prepara- cion, y composiciones insecticidas que los comprenden
DE69821985D1 (de) Ortho-anthranilamide derivate als antikoagulantien
DE60007329D1 (de) N-heterozyklische derivate als nos inhibitoren
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
EA200001217A1 (ru) Лекарственный комплекс
DE60133479D1 (de) Modifizierter tpo-agonisten antikörper
DE69813622T2 (de) Verbindungen für massenspektrometrie bestehend aus nukleinsäure-basen und arylether-massmarkern
DE60101000D1 (de) N-heterocyclische derivate als nos inhibitoren
TR199900090A2 (xx) Benzos�lfon t�revleri
BR0213140A (pt) Fungicidas de pirazol-pirimidina
BR0312675A (pt) Composto ou um sal de adição de ácido farmacêutico do mesmo,m e, métodos para tratar endometriose, e para tratar leiomioma uterino
ATE181065T1 (de) Transportvehikel für makromoleküle
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
ATE299871T1 (de) Neue zyklische depsipeptid pf1022 derivate
ATE476989T1 (de) Humanisierter monoklonaler antikörper gegen von- willebrand faktor
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
EA200501341A1 (ru) Противобактериальные индолоноксазолидиноны, промежуточные соединения для их получения и содержащие их фармацевтические композиции
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
SE9801494D0 (sv) Novel use

Legal Events

Date Code Title Description
FC Refusal